Fox Run Management L.L.C. Takes Position in Vera Therapeutics, Inc. $VERA

Fox Run Management L.L.C. purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 17,033 shares of the company’s stock, valued at approximately $863,000.

A number of other institutional investors have also made changes to their positions in the business. CenterBook Partners LP bought a new stake in shares of Vera Therapeutics in the fourth quarter worth $792,000. Los Angeles Capital Management LLC bought a new stake in shares of Vera Therapeutics in the fourth quarter worth $46,000. TD Asset Management Inc lifted its position in shares of Vera Therapeutics by 54.7% in the fourth quarter. TD Asset Management Inc now owns 325,564 shares of the company’s stock worth $16,487,000 after purchasing an additional 115,090 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Vera Therapeutics by 47.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,120,780 shares of the company’s stock worth $56,756,000 after purchasing an additional 362,214 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Vera Therapeutics by 86.9% in the fourth quarter. BNP Paribas Financial Markets now owns 474,668 shares of the company’s stock worth $24,037,000 after purchasing an additional 220,692 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on VERA shares. The Goldman Sachs Group reissued a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Wednesday, March 11th. Finally, Evercore set a $91.00 price objective on shares of Vera Therapeutics in a research report on Friday, May 15th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $10,362,498.20. This represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by insiders.

Vera Therapeutics Price Performance

Shares of VERA opened at $31.62 on Thursday. The firm has a market capitalization of $2.27 billion, a PE ratio of -5.71 and a beta of 0.93. The company’s 50-day moving average is $37.27 and its 200-day moving average is $41.40. Vera Therapeutics, Inc. has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the company earned ($0.81) EPS. Equities analysts forecast that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.